HC Wainwright Has Positive Forecast for ELVN Q2 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Equities research analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Enliven Therapeutics in a research note issued on Thursday, July 9th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.38) per share for the quarter, up from their previous forecast of ($0.41). HC Wainwright has a “Buy” rating and a $64.00 price target on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.58) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06.

ELVN has been the topic of several other reports. The Goldman Sachs Group increased their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Guggenheim initiated coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target on the stock. Mizuho increased their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, Stifel Nicolaus boosted their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $69.17.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $51.09 on Monday. The company has a fifty day simple moving average of $43.30 and a two-hundred day simple moving average of $34.86. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -30.59 and a beta of 0.24. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $52.39.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. This trade represents a 10.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 26,018 shares of company stock valued at $1,113,888. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently made changes to their positions in ELVN. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. boosted its position in shares of Enliven Therapeutics by 4.3% in the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. KBC Group NV purchased a new position in Enliven Therapeutics during the 1st quarter worth approximately $38,000. Finally, Swiss National Bank grew its stake in Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after buying an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.